Yuanqi Mi

Yuanqi Mi

Auto-generated profile, based on publicly available information

Yuanqi Mi

Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2025 in Social Science & Medicine
Verified
Journal Article
Closed access
YMYuanqi Mi
Yuanqi Mi
JWJohn Mark Wiginton
John Mark Wiginton
SMSarah M. Murray
Sarah M. Murray
ILIaah Lucas
Iaah Lucas
MVMariah Valentine-Graves
Mariah Valentine-Graves
ARAmrita Rao
Amrita Rao

3 November 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
YMYuanqi Mi
Yuanqi Mi
XWXiaofei Wang
Xiaofei Wang
YZYuhong Zeng
Yuhong Zeng
YGYang Guo
Yang Guo
PWPeicheng Wang
Peicheng Wang
MZMengge Zhou
Mengge Zhou
Durability of the initially prescribed antiretroviral therapy (ART) regimen is critical for long-term virologic suppression among people living with human immunodeficiency virus (HIV). However, data on the incidence of regimen modification and its associated factors remain limited in China. We aim to quantify the incidence of initially prescribed ART modification and identify associated baseline factors in China. Treatment-naïve adults (≥18 years) who initiated ART with complete regimen records and have documented follow-up information in Beijing, China, from 2010 to 2020 were included. The primary outcome was initially prescribed ART regimen modification. A multivariable Cox proportional hazards model was applied to evaluate factors associated with modification risk. Of 18,911 participants included, 3,725 (19.7%) participants experienced ART modification over 472,565 person-months of follow-up (PMFU), a rate of 7.9 per 1,000 PMFU. The median follow-up was 32 (IQR 13–36) months. Modification rates peaked in months 0–6: TDF + AZT + NVP and LPV/r + 3TC + AZT exhibited the highest 6-month modification rates (59.4 and 57.7 per 1,000 PMFU, respectively), whereas TDF + 3TC + EFV, the most prescribed regimen, had the lowest early switch rate (8.8 per 1,000 PMFU). In multivariable analysis, baseline white blood cell (WBC) < 4.0 × 10⁹/L and WHO stage II–IV were associated with higher modification risk; missing baseline records of WBC, hepatitis B virus or hepatitis C virus coinfection, and later calendar year of ART initiation were associated with lower modification risk; compared to EFV + 3TC + TDF, LPV/r + 3TC + AZT had the highest modification risk. TDF + 3TC + EFV was the predominant initially prescribed regimen with the highest durability, while LPV/r + 3TC + AZT had the highest modification rate. These findings underscore the need for early ART initiation, comprehensive pretreatment screening, and enhanced early monitoring—especially during the first six months—to optimize regimen selection and minimize unnecessary modification.

5 November 2026 in SSM - Mental Health
Verified
Journal Article
Open access
YMYuanqi Mi
Yuanqi Mi
KRKatherine Rucinski
Katherine Rucinski
MRMary Anne E. Roach
Mary Anne E. Roach
HSHrishikesh Sathyamoorthy
Hrishikesh Sathyamoorthy
ARAmrita Rao
Amrita Rao
KAKaitlyn Atkins
Kaitlyn Atkins

11 July 2026 in Annals of Epidemiology
Verified
Journal Article
Closed access
KRKatherine Rucinski
Katherine Rucinski
YMYuanqi Mi
Yuanqi Mi
KAKaitlyn Atkins
Kaitlyn Atkins
MRMary Anne Roach
Mary Anne Roach
ARAmrita Rao
Amrita Rao
SBStefan Baral
Stefan Baral

18 September 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
CYChenlu Yang
Chenlu Yang
YMYuanqi Mi
Yuanqi Mi
YZYuhong Zeng
Yuhong Zeng
FCFeng Cheng
Feng Cheng
HZHuatang Zeng
Huatang Zeng
MZMengge Zhou
Mengge Zhou
Background: Ainuovirine (ANV), a new non-nucleoside reverse transcriptase inhibitor, has been shown to have comparable effectiveness to efavirenz (EFV) with fewer adverse events. However, evidence on the cost-effectiveness of replacing EFV-based regimens with ANV-based regimens remains limited, particularly within the context of China’s National Free Antiretroviral Treatment Programme. Objective: This study aimed to evaluate the cost-effectiveness of ANV-based versus EFV-based regimens among people living with HIV (PLWH) in China. Methods: Decision tree-Markov models were developed to compare EFV-based and ANV-based regimens over a 15-year time horizon from a societal perspective. Model inputs, including treatment costs and adverse event risks, were mainly obtained from a multicentre Chinese cohort and field survey data. Cost-effectiveness was assessed separately for treatment-naïve and treatment-experienced populations and at the overall programme level. Outcomes included costs, quality-adjusted life-years (QALYs), adverse events and incremental cost-effectiveness ratios (ICERs). One-way, probabilistic and scenario sensitivity analyses were conducted to assess parameter and structural uncertainty. Results: Compared with the EFV-based regimen, ANV-based regimen was associated with a marked reduction in cumulative adverse events, while producing small per-person QALY gains of 0.006–0.011 at modestly higher costs across the modelled populations. ANV-based regimens generated slightly higher QALYs at modestly higher costs across all modelled populations. The ICERs were $10 030.41/QALY in treatment-naïve individuals, $3881.06/QALY in treatment-experienced individuals and $5146.18/QALY at the overall programme level, all below the prespecified willingness-to-pay threshold of three times China’s 2019 per-capita gross domestic product ($30 793.15/QALY). Sensitivity analyses showed that the results were robust, with ANV and EFV medication costs being the most influential parameters. If the half-year cost of ANV medication decreased below $361.39, the ANV-based regimen would become the dominant strategy, providing greater health benefits at lower overall costs. Conclusion: Within the context of China’s National Free Antiretroviral Treatment Programme, ANV-based regimens were cost-effective compared with EFV-based regimens among PLWH, with reduced adverse events and modest QALY gains at acceptable incremental costs. These findings support consideration of ANV-based regimens as an alternative option in future procurement and price negotiation decisions.

16 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
YMYuanqi Mi
Yuanqi Mi
AGAlex Garner
Alex Garner
MNMaguette Niang
Maguette Niang
CHChenglin Hong
Chenglin Hong
SHSean Howell
Sean Howell
SBStefan Baral
Stefan Baral
Population size estimates (PSE) for gay, bisexual, and other cisgender men who have sex with men (GBMSM) remain difficult where stigma and criminalization limit data collection and HIV resource allocation. We aim to assess whether Google Trends and a gay social networking app can provide standardized, low-cost population size estimates (PSE) for gay, bisexual, and other cisgender men who have sex with men (GBMSM) in Senegal, Ghana, Mozambique, and Indonesia. We analyzed country-level and local GT relative search volumes for “porn” and “gay porn” from September 2024 to September 2025. Pornhub global review data were applied to produce proportional GBMSM PSEs. App estimates were derived from monthly active users and extrapolated to annual users. Proportional estimates were multiplied by the male population aged 15–49 years to obtain absolute PSE and compared with UNAIDS Key Population Atlas estimates. Sensitivity analyses used survey-based multipliers and alternative search-term combinations. GTPSE ranged from 0.37% in Mozambique to 1.92% in Indonesia, while app-based estimates ranged from 0.29% in Mozambique to 1.34% in Ghana. GTPSE exceeded UNAIDS estimates in Ghana, Mozambique, and Indonesia. App-based estimates exceeded UNAIDS estimates in Ghana and Mozambique. Maputo’s estimated GBMSM proportion was substantially higher than Mozambique’s national estimate. GTPSE generally exceeded UNAIDS estimates, which may reflect underestimation in stigmatizing settings where GBMSM are less likely to be reached through field-based methods or mainstream health services. Social network app estimates were lower in some countries, highlighting variability in platform access and geographic differences in the concentration of social networks. Internet-derived data may offer a low-cost, feasible approach to GBMSM PSE in low- and middle-income settings. Further validation through digital data linkages could strengthen HIV prevention and treatment planning.